Time：2025-12-12
Recently, the Zhejiang Provincial Department of Economy and Information Technology announced the proposed list of 2025 Zhejiang Provincial Enterprise Technology Centers. Chinese Peptide Company, a subsidiary of Medtide Pharmaceuticals, successfully made the list by virtue of its profound technical innovation accumulation and outstanding industrial leading capacity. This marks the dual authoritative recognition of Chinese Peptide Company's technological innovation strength and R&D system construction by both provincial and municipal competent authorities.
The recognition of enterprise technology centers this time was strictly carried out in accordance with the requirements of the Notice on Printing and Distributing the Measures for the Administration of Hangzhou Municipal Enterprise Technology Centers (Hang Jingxinlian Zhineng〔2018〕No. 81) and the Notice on Carrying out the Recognition and Re-evaluation Work of 2025 Hangzhou Municipal Enterprise Technology Centers (Hang Jingxin Jichuang〔2025〕No. 56). After multiple rigorous procedures including independent application by enterprises, recommendation by district and county economic and information departments, review by municipal-level departments, and expert evaluation, a total of 170 enterprises were finally selected as municipal enterprise technology centers from a large number of applicants. Chinese Peptide Company stood out smoothly with its technological advantages in the fields of peptides and oligonucleotides. As an important part of Hangzhou's industrial innovation system, the recognition of enterprise technology centers aims to commend backbone enterprises in the industry with strong innovation capabilities and sound innovation mechanisms. The selection of Chinese Peptide Company is a high affirmation of its comprehensive strength in technological R&D, achievement transformation, talent training and other aspects.
Winning the recognition as both provincial and municipal enterprise technology center is not only an honor but also a responsibility for Chinese Peptide Company. In the future, taking the enterprise technology center as a new development platform, Chinese Peptide Company will continue to increase R&D investment, deepen industry-university-research collaborative innovation, break through more key core technologies in the fields of peptides and oligonucleotides, contribute to building Hangzhou into a global innovation hub, and boost the high-quality development of the global biopharmaceutical industry.
About Chinese Peptide Company (One Sentence)
Chinese Peptide Company is a peptide and oligonucleotide-focused Contract Research, Development, and Manufacturing Organization (CRDMO), offering full-cycle services ranging from early-stage discovery, pre-clinical research and clinical development to commercial-stage production.
